Repository of Research and Investigative Information

Repository of Research and Investigative Information

Baqiyatallah University of Medical Sciences

A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer

(2021) A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer. Adv Exp Med Biol. pp. 49-64. ISSN 0065-2598 (Print) 0065-2598

Full text not available from this repository.

Abstract

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer worldwide. It metastasizes rapidly and has a poor prognosis. The first-line treatment for most patients is a combination of chemotherapy and radiation. In many subjects, using targeted treatments alongside chemoradiation has shown a better outcome in terms of progression and quality of life for patients. These targeted treatments include small biological inhibiting molecules and monoclonal antibodies. In this review, we have assessed studies focused upon the treatment of non-small cell lung cancer. Some therapies are approved, such as bevacizumab and atezolizumab, while some are still in clinical trials, such as ficlatuzumab and ipilimumab, and others have been rejected due to inadequate disease control, such as figitumumab.

Item Type: Article
Keywords: Antibodies, Monoclonal/therapeutic use *Antineoplastic Agents, Immunological/therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Bevacizumab/therapeutic use *Carcinoma, Non-Small-Cell Lung/drug therapy Humans *Lung Neoplasms/drug therapy Quality of Life Lung cancer Monoclonal antibodies Non-small cell Targeted treatment
Page Range: pp. 49-64
Journal or Publication Title: Adv Exp Med Biol
Journal Index: Pubmed
Volume: 1286
Identification Number: https://doi.org/10.1007/978-3-030-55035-6₃
ISSN: 0065-2598 (Print) 0065-2598
Depositing User: مهندس مهدی شریفی
URI: http://eprints.bmsu.ac.ir/id/eprint/9379

Actions (login required)

View Item View Item